Abstract 2155: One year clinical outcomes associated with the use of a Zotarolimus eluting stent: A Single-Center Canadian Experience
Background: The use of drug eluting stents (DES) has improved clinical and angiographic outcomes by reducing the need for target vessel revascularization (TVR). Clinical outcomes associated with the use a novel DES, the Zotarolimus-eluting phosphorylcholine-coated (Endeavor®) stent are less well established. A randomized clinical trial examining the benefits of the Endeavor® stent the rates of target vessel revascularization (TVR), target lesion revascularization (TLR) and stent thrombosis (ST) rates at 9 months in a select “study population” were reported as 7.9%, 4.6% and 0.5% respectively. These studies examined the outcomes of the Endeavor® stents in patients with single and non-complex lesions, while excluding patients with Acute Coronary Syndrome (ACS), Left Main (LM) lesions or In-stent restenosis (ISR). The outcomes of the Endeavor® stents in a “real-world” population have not been studied. The objective of this study was to evaluate the safety and efficacy of Endeavor® stents in consecutive patients from a single, high volume Canadian center.
Methods & Results: The charts and angiogram reports of consecutive pts between June 2005 and June 2006, who received ≥ 1 Endeavor® stents were reviewed (n=462). In total, 667 Endeavor® stents were deployed in 462 patients. These patients were: 71% male, 65+/−9.1 year-old, 45% DM, 51% smokers, 62% HTN, 73% with dyslipidemia, and 5% with previous bypass surgery. The indications for stenting were: stable CAD 47.7%, ACS 47.1% and STEMI 5.1%. Endeavor® stents were utilized for ISR in 9% of cases. Average stent size was 19.7 +/− 5.8 × 2.9 +/− 0.3mm. At 12 month follow-up, TLR and TVR rates of 6.9% and 8.9% were observed, along with 2 cases of acute ST. There were no cases of late ST (>1 month post stent implantation). Myocardial Infarction occurred in 3.5% patients over 12 months.
Discussion: In a Canadian interventional cardiology center, TLR, TVR and ST rates of 6.9%, 8.9% and 0.6% were observed at 12 months post-implantation. Despite including patients with multiple lesions, complex lesions, ACS and ISR, the rates observed at our center were comparable to those observed in a select study population. Most importantly there were no late stent thrombosis.